
Opinion|Videos|July 3, 2024
Investigational Therapies Paving New PNH Treatment Pathways
Dr Haumschild continues leading a discussion surrounding potential treatment advancements in the PNH landscape.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Looking towards the future, what advancements do you anticipate in the treatment landscape for PNH and other complement-driven rare diseases, particularly in relation to investigational therapeutics targeting the alternative pathway?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Real-World Data Show Most CRS, ICANS Cases Happen Within 15 Days of Liso-Cel Infusion
2
Real-World Usage of Nintedanib for PPF Differs From Trial Settings
3
NPM1 MRD Status Is a Dominant Predictor of AML Relapse After AlloHCT
4
Global Burden of CLL Decreasing, But Key Challenges Remain
5














































